RecruitingNot ApplicableNCT06171139

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

Developing and Testing a Patient-centered Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Metastatic Prostate Cancer


Sponsor

University of California, San Francisco

Enrollment

80 participants

Start Date

Dec 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the tool for implementation.


Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria18

  • Stage 1:
  • Age 18-years-old or older
  • Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race including Black or African American is included.
  • Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
  • Able to understand study procedures and to comply with them for the entire length of the study.
  • Able to understand a written information sheet and willing to verbally consent.
  • Fluent in English (reading, writing, and speaking)
  • Stage 2:
  • Age 18-years-old or older
  • Identifies as Black or African-American, by either chart documentation or participant self-report. Mixed-race including Black or African-American is included.
  • Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
  • Able to understand study procedures and to comply with them for the entire length of the study.
  • Fluent in English (reading, writing, and speaking).
  • Anticipated discussion of TGT within 0-90 days of enrollment, per treating oncology provider's discretion. TGT involves use of any cancer genetic sequencing (whether standard-of-care or part of a research protocol) via any one of the following:
  • Somatic DNA testing of already-collected tissue.
  • Somatic DNA testing of tissue to be collected in the future via biopsy, surgery, or other procedure.
  • Blood-based DNA testing to evaluate for circulating tumor DNA.
  • Able to understand a written informed consent document and willing to sign it.

Exclusion Criteria1

  • Contraindication to any study-related procedure or assessment in either stage.

Interventions

OTHERCounseling Tool

Non-therapeutic educational intervention

OTHERQuestionnaires

Participants will complete questionnaires online, via mail, by telephone, or in person per participant preference.


Locations(1)

University of California

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06171139


Related Trials